Teriparatide therapy as an adjuvant for tissue engineering and integration of biomaterials

Materials

Volumn 4, Issue 6, 2011, Pages 1117-1131

  Dhillon, Robinder S ^a   Schwarz, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Allograft repair; Bio integration; Biomaterials; Fracture healing; Non union; Osseointegration; Parathyroid hormone (PTH); Teriparatide

Indexed keywords

BIO-INTEGRATION; FRACTURE HEALING; NON-UNION; OSSEOINTEGRATION; PARATHYROID HORMONES; TERIPARATIDE;

BIOLOGICAL MATERIALS; BIOMATERIALS; CELL CULTURE; DRUG THERAPY; INTEGRATION; REPAIR; TISSUE ENGINEERING;

BONE;

EID: 84878884653     PISSN: None     EISSN: 19961944     Source Type: Journal    
DOI: 10.3390/ma4061117     Document Type: Article

References (75)

1. Zhang, X.P.; Xie, C.; Lin, A.S.P.; Ito, H.; Awad, H.; Lieberman, J.R.; Rubery, P.T.; Schwarz, E.M.; O'Keefe, R.J.; Guldberg, R.E. Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. J. Bone Miner. Res. 2005, 20 (12), 2124-2137.
2. Foundation, O.C. Oral Cancer Facts. 2010. Available online: http://www.oralcancerfoundation.org/ facts/index.htm (accessed on 6 May 2011).
3. Stansbury, L.G.; Lalliss, S.J.; Branstetter, J.G.; Bagg, M.R.; Holcomb, J.B. Amputations in U.S. military personnel in the current conflicts in Afghanistan and Iraq. J. Orthop. Trauma 2008, 22 (1), 43-46.
4. Khan, S.N.; Cammisa, F.P., Jr.; Sandhu, H.S.; Diwan, A.D.; Girardi, F.P.; Lane, J.M. The biology of bone grafting. J. Am. Acad. Orthop. Surg. 2005, 13 (1), 77-86.
5. Beaver, R.; Brinker, M.R.; Barrack, R.L. An analysis of the actual cost of tibial nonunions. J. La. State Med. Soc. 1997, 149 (6), 200-206.
6. Xie, C.; Reynolds, D.; Awad, H.; Rubery, P.T.; Pelled, G.; Gazit, D.; Guldberg, R.E.; Schwarz, E.M.; O.Keefe, R.J.; Zhang, X. Structural bone allograft combined with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering. Tissue Eng. 2007, 13 (3), 435-445.
7. Harada, S.; Rodan, G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423 (6937), 349-355.
8. Kronenberg, H.M.; Bringhurst, F.R.; Nussbaum, S.; Juppner, H.; Abou-Samra, A.B.; Segre, G.V.; Potts, J.T., Jr. Parathyroid hormone: biosynthesis, secretion, chemistry, and action. In Handbook of Experimental Pharmacology: Physiology and Pharmacology of Bone; Mundy, G.R., Martin, T.J., Heidelberg, M., Eds.; Springer-Verlag KG: Heidelberg, Germany, 1993; pp. 185-201.
9. Potts, J.T., Jr.; Juppner, H. Parathyroid Hormone and Parathyroid Hormone-Related Peptide in Calcium Homeostasis, Bone Metabolism, and Bone Development: The Proteins, Their Genes, and Receptors. In Metabolic Bone Disease and Clinically Related Disorders; Avioli, L.V., Krane, S.M., Eds.; Academic Press: New York, NY, USA, 1997; pp. 51-94.
10. Brown, E.M.; Gamba, G.; Riccardi, D.; Lombardi, M.; Butters, R.; Kifor, O.; Sun, A.; Hediger, M.A.; Lytton, J.; Hebert, S.C. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993, 366 (6455), 575-580.
11. Jilka, R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40 (6), 1434-1446.
12. Neer, R.M.; Arnaud, C.D.; Zanchetta, J.R.; Prince, R.; Gaich, G.A.; Reginster, J.Y.; Hodsman, A.B.; Eriksen, E.F.; Ish-Shalom, S.; Genant, H.K.; et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344 (19), 1434-1441.
13. Bukata, S.V.; Puzas, J.E. Orthopedic uses of teriparatide. Curr. Osteoporos. Rep. 2010, 8 (1), 28-33.
14. Ryder, K.M.; Tanner, S.B.; Carbone, L.; Williams, J.E.; Taylor, H.M.; Bush, A.; Pintea, V.; Watsky, M.A. Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J. Bone Miner. Metab. 2010, 28 (2), 233-239.
15. Saag, K.G.; Zanchetta, J.R.; Devogelaer, J.P.; Adler, R.A.; Eastell, R.; See, K.; Krege, J.H.; Krohn, K.; Warner, M.R. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009, 60 (11), 3346-3355.
16. Finkelstein, J.S.; Wyland, J.J.; Lee, H.; Neer, R.M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2010, 95 (4), 1838-1845.
17. Kakar, S.; Einhorn, T.A.; Vora, S.; Miara, L.J.; Hon, G.; Wigner, N.A.; Toben, D.; Jacobsen, K.A.; Al-Sebaei, M,O.; Song, M.; et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J. Bone Miner. Res. 2007, 22 (12), 1903-1912.
18. Etoh, M.; Yamaguchi, A. Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone. J. Bone Miner. Metab. 2010, 28 (6), 641-649.
19. Ito, M. Parathyroid and bone. Effect of parathyroid hormone on bone quality. Clin. Calcium 2007, 17 (12), 1858-1864.
20. Nishida, S.; Yamaguchi, A.; Tanizawa, T.; Endo, N.; Mashiba, T.; Uchiyama, Y.; Suda, T.; Yoshiki, S.; Takahashi, H.E. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 1994, 15 (6), 717-723.
21. Jilka, R.L.; O'Brien, C.A.; Ali, A.A.; Roberson, P.; Weinstein, R.S.; Manolagas, S.C. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 2009, 44 (2), 275-286.
22. Jilka, R.L.; Weinstein, R.S.; Bellido, T.; Roberson, P.; Parfitt, A.M.; Manolagas, S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 1999, 104 (4), 439-446.
23. Bellido, T.; Ali, A.A.; Gubrij, I.; Plotkin, L.I.; Fu, Q.; O.Brien, C.A.; Manolagas, S.C.; Jilka, R.L. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146 (11), 4577-4583.
24. Uzawa, T.; Hori, M.; Ejiri, S.; Ozawa, H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 1995, 16 (4), 477-484.
25. Horwitz, M.J.; Tedesco, M.B.; Sereika, S.M.; Syed, M.A.; Garcia-Ocaña, A.; Bisello, A.; Hollis, B.W.; Rosen, C.J.; Wysolmerski, J.J.; Dann, P.; et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J. Bone Miner. Res. 2005, 20 (10), 1792-1803.
26. Fu, Q.; Jilka, R.L.; Manolagas, S.C.; O'Brien, C.A. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 2002, 277 (50), 48868-48875.
27. Tiyapatanaputi, P.; Rubery, P.T.; Carmouche, J.; Schwarz, E.M.; O.keefe, R.J.; Zhang, X. A novel murine segmental femoral graft model. J. Orthop. Res. 2004, 22 (6), 1254-1260.
28. Einhorn, T.A.; Majeska, R.J.; Mohaideen, A.; Kagel, E.M.; Bouxsein, M.L.; Turek, T.J.; Wozney, J.M. A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J. Bone Jt. Surg. Am. Vol. 2003, 85-A (8), 1425-1435.
29. Einhorn, T.A. Clinical applications of recombinant human BMPs: early experience and future development. J. Bone Jt. Surg. Am. Vol. 2003, 85-A (Suppl. 3), 82-88.
30. Bruder, S.P.; Kurth, A.A.; Shea, M.; Hayes, W.C.; Jaiswal, N.; Kadiyala, S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J. Orthop. Res. 1998, 16 (2), 155-162.
31. Yoon, S.T.; Boden, S.D. Osteoinductive molecules in orthopaedics: Basic science and preclinical studies. Clin. Orthop. Relat. Res. 2002, 395 (2), 33-43.
32. Valentin-Opran, A.; Wozney, J.; Csimma, C.; Lilly, L.; Riedel, G.E. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin. Orthop. Relat. Res. 2002, 395 (2), 110-120.
33. Rickard, D.J.; Wang, F.L.; Rodriguez-Rojas, A.M.; Wu, Z.; Trice, W.J.; Hoffman, S.J.; Votta, B.; Stroup, G.B.; Kumar, S.; Nuttall, M.E. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006, 39 (6), 1361-1372.
34. Kaback, L.A.; Soung do, Y.; Naik, A.; Geneau, G.; Schwarz, E.M.; Rosier, R.N.; O'Keefe, R.J.; Drissi, H. Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J. Cell. Biochem. 2008, 105 (1), 219-226.
35. Yang, C.; Frei, H.; Burt, H.M.; Rossi, F. Effects of continuous and pulsatile PTH treatments on rat bone marrow stromal cells. Biochem. Biophys. Res. Commun. 2009, 380 (4), 791-796.
36. Moutsatsos, I.K.; Turgeman, G.; Zhou, S.; Kurkalli, B.G.; Pelled, G.; Tzur, L.; Kelley, P.; Stumm, N.; Mi, S.; Müller, R.; et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol. Ther. 2001, 3 (4), 449-461.
37. Gazit, D.; Turgeman, G.; Kelley, P.; Wang, E.; Jalenak, M.; Zilberman, Y.; Moutsatsos, I. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J. Gene Med. 1999, 1 (2), 121-133.
38. Turgeman, G.; Pittman, D.D.; Müller, R.; Kurkalli, B.G.; Zhou, S.; Pelled, G.; Peyser, A.; Zilberman, Y.; Moutsatsos, I.K.; Gazit, D. Engineered human mesenchymal stem cells: A novel platform for skeletal cell mediated gene therapy. J. Gene Med. 2001, 3 (3), 240-251.
39. Dayoub, H.; Dumont, R.J.; Li, J.Z.; Dumont, A.S.; Hankins, G.R.; Kallmes, D.F.; Helm, G.A. Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents. Tissue Eng. 2003, 9 (2), 347-356.
40. Virk, M.S.; Sugiyama, O.; Park, S.H.; Gambhir, S.S.; Adams, D.J.; Drissi, H.; Lieberman, J.R. "Same Day" ex-vivo regional gene therapy: A novel strategy to enhance bone repair. Mol. Ther. 2011, 19 (5), 960-968.
41. Aslan, H.; Zilberman, Y.; Kandel, L.; Liebergall, M.; Oskouian, R.J.; Gazit, D.; Gazit, Z. Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells. Stem Cells 2006, 24 (7), 1728-1737.
42. Aslan, H.; Zilberman, Y.; Arbeli, V.; Sheyn, D.; Matan, Y.; Liebergall, M.; Li, J.Z.; Helm, G.A.; Gazit, D.; Gazit, Z. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng. 2006, 12 (4), 877-889.
43. Boden, S.D.; Kang, J.; Sandhu, H.; Heller, J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: A prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002, 27 (23), 2662-2673.
44. Jilka, R.L.; Almeida, M.; Ambrogini, E.; Han, L.; Roberson, P.K.; Weinstein, R.S.; Manolagas, S.C. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell 2010, 9 (5), 851-867.
45. Andreassen, T.T.; Ejersted, C.; Oxlund, H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J. Bone Miner. Res. 1999, 14 (6), 960-968.
46. Nakajima, A.; Shimoji, N.; Shiomi, K.; Shimizu, S.; Moriya, H.; Einhorn, T.A.; Yamazaki, M. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J. Bone Miner. Res. 2002, 17 (11), 2038-2047.
47. Nakazawa, T.; Nakajima, A.; Shiomi, K.; Moriya, H.; Einhorn, T.A.; Yamazaki, M. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005, 37 (5), 711-719.
48. Kaback, L.A.; Soung do, Y.; Naik, A.; Geneau, G.; Schwarz, E.M.; Rosier, R.N.; O.Keefe, R.J.; Drissi, H. Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J. Cell Biochem. 2008, 105 (1), 219-226.
49. Kaback, L.A.; Soung do, Y.; Naik, A.; Smith, N.; Schwarz, E.M.; O.Keefe, R.J.; Drissi, H. Osterix/Sp7 regulates mesenchymal stem cell mediated endochondral ossification. J. Cell. Physiol. 2008, 214 (1), 173-182.
50. Okazaki, K.; Jingushi, S.; Ikenoue, T.; Urabe, K.; Sakai, H.; Iwamoto, Y. Expression of parathyroid hormone-related peptide and insulin-like growth factor I during rat fracture healing. J. Orthop. Res. 2003, 21 (3), 511-520.
51. Kakar, S.; Einhorn, T.A.; Vora, S.; Miara, L.J.; Hon, G.; Wigner, N.A.; Toben, D.; Jacobsen, K.A.; Al-Sebaei, M.O.; Song, M.; et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J. Bone Miner. Res. 2007, 22 (12), 1903-1912.
52. Komatsu, D.E.; Brune, K.A.; Liu, H.; Schmidt, A.L.; Han, B.; Zeng, Q.Q.; Yang, X.H.; Nunes, J.S.; Lu, Y.F.; Geiser, A.G.; et al. Longitudinal in vivo analysis of the region-specific efficacy of parathyroid hormone in a rat cortical defect model. Endocrinology 2009, 150 (4), 1570-1579.
53. Skripitz, R.; Andreassen, T.T.; Aspenberg, P. Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber. A dose-response study. J. Bone Jt. Surg. Br. Vol. 2000, 82 (1), 138-141.
54. Andreassen, T.T.; Willick, G.E.; Morley, P.; Whitfield, J.F. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif. Tissue Int. 2004, 74 (4), 351-356.
55. Komatsubara, S.; Mori, S.; Mashiba, T.; Nonaka, K.; Seki, A.; Akiyama, T.; Miyamoto, K.; Cao, Y.; Manabe, T.; Norimatsu, H. Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 2005, 36 (4), 678-687.
56. Manabe, T.; Mori, S.; Mashiba, T.; Kaji, Y.; Iwata, K.; Komatsubara, S.; Seki, A.; Sun, Y.X.; Yamamoto,Y. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007, 40 (6), 1475-1482.
57. Quinn, J.M.; Elliott, J.; Gillespie, M.T.; Martin, T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139 (10), 4424-4427.
58. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998, 95 (7), 3597-3602.
59. Alkhiary, Y.M.; Gerstenfeld, L.C.; Krall, E.; Westmore, M.; Sato, M.; Mitlak, B.H.; Einhorn, T.A. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J. Bone Jt. Surg. Am. Vol. 2005, 87 (4), 731-741.
60. Pierroz, D.D.; Bonnet, N.; Baldock, P.A.; Ominsky, M.S.; Stolina, M.; Kostenuik, P.J.; Ferrari, S.L. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J. Biol. Chem. 2010, 285 (36), 28164-28173.
61. Chavassieux, P.; Karsdal, M.A.; Segovia.Silvestre, T.; Neutzsky-Wulff, A.V.; Chapurlat, R.; Boivin, G.; Delmas, P.D. Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J. Bone Miner. Res. 2008, 23 (7), 1076-1083.
62. Martin, T.J. Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol. Metab. 2004, 15 (2), 49-50.
63. Reynolds, D.G.; Shaikh, S.; Papuga, M.O.; Lerner, A.L.; O'Keefe, R.J.; Schwarz, E.M.; Awad, H.A. muCT-based measurement of cortical bone graft-to-host union. J. Bone Miner. Res. 2009, 24 (5), 899-907.
64. Oteo-Alvaro, A.; Moreno, E. Atrophic humeral shaft nonunion treated with teriparatide (rh PTH 1-34): A case report. J. Shoulder Elbow Surg. 2010, 19 (7), e22-e28.
65. Rubery, P.T.; Bukata, S.V. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: A report of 3 cases. J. Spinal Disord. Tech. 2010, 23 (2), 151-155.
66. Chintamaneni, S.; Finzel, K.; Gruber, B.L. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos. Int. 2010, 21 (6), 1059-1063.
67. Puzas, J.E.; Houck, J.; Bukata, S.V. Accelerated fracture healing. J. Am. Acad. Orthop. Surg. 2006, 14 (10), S145-S151.
68. Resmini, G.; Iolascon, G. 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin. Exp. Res. 2007, 19 (Suppl. 4), 30-31.
69. Peichl, P.; Holzer, G. Parathyroid Hormone 1-84 Accelerates Fracture Healing in Pubic Bones of Elderly Osteoporotic Women. In Proceedings of ASBMR 31st Annual Meeting, Colorado, CO, USA, 11-15 September 2009.
70. Zati, A.; Sarti, D.; Malaguti, M.C.; Pratelli, L. Teriparatide in the treatment of a loose hip prosthesis. J. Rheumatol. 2011, 38 (4), 778-780.
71. Aspenberg, P.; Genant, H.K.; Johansson, T.; Nino, A.J.; See, K.; Krohn, K.; García-Hernández, P.A.; Recknor, C.P.; Einhorn, T.A.; Dalsky, G.P.; et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J. Bone Miner. Res. 2010, 25 (2), 404-414.
72. Aspenberg, P.; Johansson, T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010, 81 (2), 234-236.
73. Tsujimoto, M.; Chen, P.; Miyauchi, A.; Sowa, H.; Krege, J.H. PINP as an aid for monitoring patients treated with teriparatide. Bone 2011, 48 (4), 798-803.
74. Yu, E.W.; Neer, R.M.; Lee, H.; Wyland, J.J.; de la Paz, A.V.; Davis, M.C.; Okazaki, M.; Finkelstein, J.S. Time-dependent changes in skeletal response to teriparatide: Escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. Bone 2011, 48 (4), 713-719.
75. Aleksyniene, R.; Thomsen, J.S.; Eckardt, H.; Bundgaard, K.G.; Lind, M.; Hvid, I. Parathyroid hormone PTH(1-34) increases the volume, mineral content, and mechanical properties of regenerated mineralizing tissue after distraction osteogenesis in rabbits. Acta Orthop. 2009, 80 (6), 716-723.